Avalo Therapeutics (AVTX) to Post Quarterly Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.5827) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. On average, analysts expect Avalo Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $18.05 on Tuesday. The stock has a market capitalization of $954.85 million, a PE ratio of -3.31 and a beta of 0.80. Avalo Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $24.27. The business has a fifty day moving average price of $17.05 and a two-hundred day moving average price of $16.21.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Mizuho raised their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. HC Wainwright cut their price target on shares of Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Weiss Ratings lowered shares of Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Finally, Wolfe Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.80.

Insider Activity at Avalo Therapeutics

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total value of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares in the company, valued at approximately $73,297.78. This trade represents a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider directly owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 77,513 shares of company stock valued at $1,560,121. 4.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the second quarter valued at $56,000. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at about $143,000. Jump Financial LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $238,000. Persistent Asset Partners Ltd acquired a new stake in shares of Avalo Therapeutics in the fourth quarter valued at about $274,000. Finally, Hudson Bay Capital Management LP bought a new position in shares of Avalo Therapeutics during the fourth quarter worth about $305,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.